Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials

Title:Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials

Volume: 17 Issue: 9

Author(s): Hadeer Mohamed, Mostafa Eltobgy and Omar Abdel-Rahman*

Affiliation:

• Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo,Egypt

Keywords: Mesothelioma, tremelimumab, ipilimumab, pembrolizumab, immune, prognostic value.

Abstract: Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.

Cite this article as:

Mohamed Hadeer, Eltobgy Mostafa and Abdel-Rahman Omar*, Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (9) . https://dx.doi.org/10.2174/1871520617666170102151918